Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis

References

• Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003; 24: 595–602
   PubMed Web of Science ®Google Scholar
• Waszczykowska E, Robak E, Wozniacka A, Narbutt J, Torzecka JD, Sysa-Jedrzejowska A. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Mediat Inflamm 1999; 8: 93–100
   PubMed Web of Science ®Google Scholar
• Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 241–248
   PubMed Web of Science ®Google Scholar
• Kaplan MJ. Apoptosis in systemic lupus erythematosus. Clin Immunol 2004; 112: 210–218
   PubMed Web of Science ®Google Scholar
• Westerweel PE, Luyten RKMAC, Koomas HA, Derksen RHWM, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1384–1396
   PubMedGoogle Scholar
• Alves JD, Ames PRJ. Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome. Immunobiology 2003; 207: 23–28
   PubMed Web of Science ®Google Scholar
• Kovacic P, Jacintho JD. Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: unifying theme of oxidative stress. Mini Rev Med Chem 2003; 3: 568–575
   PubMed Web of Science ®Google Scholar
• Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, Horkko S, Witztum JL. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192–200
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Leung VYF, Griffith JF, Benzie IFF, Lim PL, Whitney B, Lee VWY, Lee KKC, Thomas GN, Tomlinson B. Effects of Vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol 2004; 32: 275–282
   Web of Science ®Google Scholar
• Evans MD, Cooke MS, Akil M, Samanta A, Lunec J. Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Comm 2000; 273: 894–898
   PubMed Web of Science ®Google Scholar
• Lunec J, Herbert K, Blount S, Griffiths HR, Emery P. 8-Hydroxydeoxyguanosine. A marker of oxidative damage in systemic lupus erythematosus. FEBS Lett 1994; 348: 131–138
   PubMed Web of Science ®Google Scholar
• Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005; 1703: 93–109
   PubMed Web of Science ®Google Scholar
• Morgan PE, Sturgess AD, Davies MJ. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2069–2079
   PubMed Web of Science ®Google Scholar
• Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol 2005; 19: 785–798
   PubMedGoogle Scholar
• Manger K, Manger P, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, Harrer T, Kalden JR. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 1065–1070
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995; 22: 1265–1270
   PubMed Web of Science ®Google Scholar
• Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A, Darnell A, Ingelmo M. Cardiovascular risk factors and the long-term outcome of lupus nephritis. Q J Med 2001; 91: 19–26
   Google Scholar
• Serban MG, Tanaseanu S, Bara C. Oxidant stress and antioxidant protection in lupus nephropathy. Rom J Intern Med 1996; 34: 105–109
   PubMedGoogle Scholar
• Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology 2003; 42: 117–122
   PubMedGoogle Scholar
• Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. P Assoc Am Physician 1999; 111: 611–621
   PubMedGoogle Scholar
• Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Hochberg MC. Letter to the Editor. Arthritis Rheum 1997;40:1725.
   Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–640
   PubMed Web of Science ®Google Scholar
• Reinheckel T, Korn S, Mohring S, Augustin W, Halangk W, Schild L. Adaptation of protein carbonyl detection to the requirements of proteome analysis demonstrated for hypoxia/reoxygenation in isolated rat liver mitochondria. Arch Biochem Biophys 2000; 376: 59–65
   PubMedGoogle Scholar
• Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 1996; 68: 850–858
   PubMed Web of Science ®Google Scholar
• Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M. Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J Biol Chem 2003; 278: 45082–45093
   PubMed Web of Science ®Google Scholar
• Rabilloud T. Mechanisms of protein silver staining in polyacrylamide gels: a 10-year synthesis. Electrophoresis 1990; 11: 785–794
   PubMed Web of Science ®Google Scholar
• Saunders NFW, Ng C, Raftery M, Guilhaus M, Goodchild A, Cavicchioli R. Proteomic and computational analysis of secreted proteins with type I signal peptides from the Antarctic archaeon Methanococcoides burtonii. J Proteome Res 2006; 5: 2457–2464
   PubMedGoogle Scholar
• Fredenrich A, Giroux LM, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res 1997; 38: 1421–1432
   PubMedGoogle Scholar
• Tilly P, Sass C, Vincent-Viry M, Aguillon D, Siest G, Visvikis S. Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas cohort. J Lipid Res 2003; 44: 430–436
   PubMed Web of Science ®Google Scholar
• Hodis HN, Quismorio FPJ, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661–665
   PubMedGoogle Scholar
• Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169–176
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC. Free radicals in biology and medicine3rd ed. Oxford University Press, New York 1999
   Google Scholar
• Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radical Res 2000; 33: S99–S108
   PubMed Web of Science ®Google Scholar
• Hayashi T, Era S, Kawai K, Imai H, Nakamura K, Onda E, Yoh M. Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology 2000; 6: 237–243
   Google Scholar
• Sogami M, Era S, Nagoka S, Kuwata K, Kida K, Shigemi J, Miura K, Suzuki E, Muto Y, Tomita E, Hayano S, Sawada S, Noguchi K, Miyata S. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr 1985; 332: 19–27
   PubMed Web of Science ®Google Scholar
• Kadota K, Yui Y, Hattori R, Murohara Y, Kawai C. Decreased sulfhydryl groups of serum albumin in coronary artery disease. Jpn Circ J 1991; 55: 937–941
   PubMedGoogle Scholar
• Beal MF. Oxidative modified proteins in aging and disease. Free Radical Biol Med 2002; 32: 797–803
   PubMed Web of Science ®Google Scholar
• Rottoli P, Magi B, Cianti R, Bargagli E, Vagaggini C, Nikiforakis N, Pallini V, Bini L. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005; 5: 2612–2618
   PubMed Web of Science ®Google Scholar
• Chapman ML, Rubin BR, Gracy RW. Increased carbonyl content of proteins in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1989; 16: 15–18
   PubMed Web of Science ®Google Scholar
• Lemarechal H, Allanore Y, Chenevier-Gobeaux C, Kahan A, Ekindjian OG, Borderie D. Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy. Clin Chim Acta 2006; 372: 147–153
   PubMedGoogle Scholar
• van Dijk KW, Rensen PCN, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 2004; 15: 239–246
   PubMed Web of Science ®Google Scholar
• Batal R, Tremblay M, Barrett PHR, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 2000; 41: 706–718
   PubMedGoogle Scholar
• Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102: 1886–1892
   PubMed Web of Science ®Google Scholar
• Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533–539
   PubMed Web of Science ®Google Scholar
• Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus—evidence of increased oxidative stress and dyslipidaemia. Rheumatology 2003; 42: 758–762
   PubMed Web of Science ®Google Scholar
• Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 551–565
   PubMed Web of Science ®Google Scholar
• Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 1431–1445
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539–545
   PubMed Web of Science ®Google Scholar
• Eaton CB. Traditional and emerging risk factors for cardiovascular disease. Prim Care Clin Office Pract 2005; 32: 963–976
   PubMedGoogle Scholar
• Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 2001; 30: 436–443
   PubMedGoogle Scholar
• Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta 2001; 312: 13–23
   PubMed Web of Science ®Google Scholar
• Steel LF, Trotter MG, Nakajima PB, Mattu TS. Efficient and specific removal of albumin from human serum samples. Mol Cell Proteomics 2003; 2: 262–270
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee EY, Lee JS, Kim HY, Park JM, Kwon MS, Park YK, Lee HJ, Kang MJ, Kim JY, Yoo JS, Park SJ, Cho JW, Kim HS, Paik YK. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics 2005; 5: 3386–3396
   PubMed Web of Science ®Google Scholar
• Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257: 485–495
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–2337
   PubMed Web of Science ®Google Scholar